All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Completed, but no date, and reported results | 2006-000644-13 | Multicenter, randomized, controlled study to compare palonosetron plus dexamethasone before chemotherapy administration versus the same regimen with dexamethasone continuing on Days 2 and 3 in prevent... | bad-data | |
Completed, but no date, and reported results | 2006-003137-32 | A randomized, open label, multicenter phase II study of first line therapy with Sorafenib in association with Interleukin 2 versus Sorafenib alone in patients with unresectable and/or metastatic renal... | bad-data | |
Completed, but no date Terminated | 2008-001355-21 | First Line UFT, OXALIPLATIN and ERBITUX combination (TEGAFOX-E) in Elderly (≥ 70 years) metastatic colorectal patients: a Phase II ITMO study. | bad-data | |
Ongoing | 2008-007152-94 | Efficacy and Safety of RAD001 (Everolimus) in Patients Affected by Biliary Tract Cancer Progressing After Prior Chemotherapy: a Phase II I.T.M.O. Study | not-yet-due | |
Completed, but no date | 2008-007153-13 | An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment | bad-data | |
Not reported | 2008-008749-39 | Capecitabine in combination with Oxaliplatin, Irinotecan and Bevacizumab (COI-B regimen) as First-Line therapy for metastatic colorectal cancer: a Phase II I.T.M.O. study. | 2014-03-06 | due-trials |
Completed, but no date, and reported results | 2012-004539-22 | An open label, single arm, phase II study to evaluate the activity and toxicity of Panitumumab in pre-treated patients with advanced well differentiated neuroendocrine tumor (G1 and G2) Studio di f... | bad-data |